Search

Your search keyword '"Schalm, Stefanie"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Schalm, Stefanie" Remove constraint Author: "Schalm, Stefanie" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
24 results on '"Schalm, Stefanie"'

Search Results

1. Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma

2. BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.

4. P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS.

6. Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

7. Abstract 3934: KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)

8. Abstract 3328: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC

11. Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)

12. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

14. Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition

16. Molecular Mechanism of mTOR downstream signaling

17. Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes

18. Abstract LB-164: IDH mutations and tumorgenicity

24. Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma.

Catalog

Books, media, physical & digital resources